| Not Yet Recruiting | An Open-Label, Single-Arm, Dose-Escalation Phase I Study Evaluating the Safety, Tolerability, and Preliminary NCT07461727 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 1 |
| Recruiting | EQUAL: EGFR ctDNA QUantative Assessment for Lung Cancer Screening in Asian and Latinx Populations NCT06716580 | Dana-Farber Cancer Institute | N/A |
| Recruiting | Whole Body HER3 Quantification With Radiolabelled Patritumab Deruxtecan (HER3-DXd) PET/CT NCT06222489 | The Netherlands Cancer Institute | Phase 2 |
| Recruiting | Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal Metasta NCT06643000 | Henan Cancer Hospital | N/A |
| Not Yet Recruiting | Osimertinib and Etoposide as First-Line Treatment in Osimertinib-Resistant Advanced EGFR-Mutant NSCLC NCT06436144 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | Phase 2 |
| Recruiting | Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells NCT06186401 | Hideho Okada, MD, PhD | Phase 1 |
| Not Yet Recruiting | Adjuvant Target Therapy Guided by ctDNA-MRD in Patients With EGFR-mutant II-IIIA Non-small Cell Lung Cancer (E NCT06323148 | Fudan University | Phase 3 |
| Recruiting | Neoadjuvant Almonertinib Followed by Chemo-immunotherapy in II-IIIB EGFR-mutant NSCLC NCT06300424 | Guangdong Provincial People's Hospital | Phase 2 |
| Recruiting | Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients NCT06071013 | China Medical University Hospital | Phase 1 / Phase 2 |
| Unknown | Applying Mobile Healthcare Education to Improve Cutaneous Self-care Capability NCT06291688 | National Taiwan University Hospital | N/A |
| Not Yet Recruiting | The Efficacy of Double-dose Furmonertinib in the Treatment of Patients With Slow Osimertinib-resistant NSCLC NCT06117644 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | — |
| Not Yet Recruiting | Osimertinib Combined With Aspirin Neoadjuvant Therapy for Resectable EGFR Mutated NSCLC Patients. NCT06018688 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | Phase 2 |
| Recruiting | Nitroglycerin Plus Radiotherapy Versus Conventional Radiotherapy in Patients With Lung Cancer. NCT06238882 | Instituto Nacional de Cancerologia de Mexico | N/A |
| Not Yet Recruiting | A Pilot Study to Understand the Impact of Therapy With Tumour Treating Fields (TTFields) in NSCLC NCT05698264 | Nir Peled | N/A |
| Active Not Recruiting | Real-Time Monitoring of Symptoms in Lung Cancer Patients Receiving Oral Targeted Therapies NCT05370469 | University of Virginia | N/A |
| Terminated | Osimertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR Mutant NSCLC NCT04908956 | ETOP IBCSG Partners Foundation | Phase 2 |
| Unknown | Tislelizumab +Bevacizumab+pc for Untreated EGFR+ and High PD-L1 Non-squamous NSCLC NCT05394233 | Sichuan Cancer Hospital and Research Institute | Phase 2 |
| Completed | Feasibility of Intratumoral Washing Fluid for Detecting EGFR Mutations in Lung Cancer NCT05517083 | Pusan National University Hospital | N/A |
| Unknown | Efficacy and Safety of Neoantigen Peptide Vaccine in the Treatment of Advanced NSCLC Progressed After EGFR-TKI NCT06095934 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | N/A |
| Recruiting | Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resecta NCT05503667 | Shanghai Pulmonary Hospital, Shanghai, China | Phase 2 |
| Terminated | (HARMONY) Study of BLU-701 in EGFR-mutant NSCLC NCT05153408 | Blueprint Medicines Corporation | Phase 1 |
| Recruiting | Exploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-po NCT05598528 | Second Xiangya Hospital of Central South University | — |
| Unknown | Almonertinib Treats Advanced NSCLC Patients With EGFR Mutations Who Are Safety Intolerant After Osimertinib Tr NCT04882345 | Shanghai Chest Hospital | Phase 2 |
| Terminated | (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC NCT04862780 | Blueprint Medicines Corporation | Phase 1 |
| Active Not Recruiting | Osimertinib Monotherapy or Combination With Chemotherapy for Advanced NSCLC Concurrent EGFR and TP53 Mutations NCT04695925 | Li Zhang, MD | Phase 3 |
| Recruiting | A Study to Evaluate the Efficacy of Osimertinib With Early Intervention SRS Treatment Compared to the Continua NCT05033691 | Hadassah Medical Organization | N/A |
| Terminated | Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients NCT04512430 | Fundación GECP | Phase 2 |
| Completed | Efficacy of Targeted Therapy Combined Chemotherapy in Advanced EGFR Positive NSCLC Patients NCT04552613 | The Fourth Affiliated Hospital of Zhejiang University School of Medicine | N/A |
| Unknown | Almonertinib/Pemetrexed/Carboplatin in EGFR T790M+ Advanced Lung Cancer NCT04592666 | Fudan University | Phase 2 |
| Completed | Neoadjuvant Afatinib Therapy for Potentially Resectable Stage III EGFR Mutation-Positive Lung Adenocarcinoma NCT04201756 | Shanghai Pulmonary Hospital, Shanghai, China | Phase 2 |
| Unknown | Osimertinib for Russian EGFR T790M Mutation-positive NSCLC Patients Who Progressed on or After EGFR TKI Therap NCT05314296 | N.N. Blokhin National Medical Research Center of Oncology | — |
| Unknown | Gefitinib With Anlotinib in Advanced Non-squamous NSCLC Patients With Uncleared Plasma ctDNA EGFRm After First NCT04358562 | Second Affiliated Hospital of Nanchang University | Phase 2 |
| Recruiting | Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation NCT04322890 | Hunan Province Tumor Hospital | Phase 2 |
| Completed | D-0316 Versus Icotinib in Patients With Locally Advanced or Metastatic EGFR Sensitising Mutation Positive NSCL NCT04206072 | Betta Pharmaceuticals Co., Ltd. | Phase 2 / Phase 3 |
| Recruiting | Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer NCT04085315 | Collin Blakely | Phase 1 |
| Completed | A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squam NCT04042558 | Centre Francois Baclesse | Phase 2 |
| Active Not Recruiting | Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage 2-3 Non-small L NCT04013542 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer NCT03909334 | Xiuning Le | Phase 2 |
| Completed | First-in-Human Phase I/II Study of FHND-9041 in Patients With EGFR Mutated Advanced Non-Small Cell Lung Cancer NCT06521034 | Yongchang Zhang | Phase 1 / Phase 2 |
| Completed | 18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients with EGFR Activated Recurrent Gliobl NCT03732352 | Jonsson Comprehensive Cancer Center | Phase 2 |
| Completed | A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers NCT03755102 | Memorial Sloan Kettering Cancer Center | EARLY_Phase 1 |
| Completed | First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) Metas NCT03653546 | Alpha Biopharma (Jiangsu) Co., Ltd. | Phase 2 / Phase 3 |
| Unknown | EGFR-TKIs Combine With Anlotinib as First-line Treatment for Patients With Advanced EGFR Mutation-positive NSC NCT03720873 | Fujian Cancer Hospital | Phase 2 |
| Unknown | Icotinib as Consolidation Therapy After Chemoradiotherapy in EGFR-Mutant Stage IIIA-IIIB Non-small Cell Lung C NCT03396185 | Betta Pharmaceuticals Co., Ltd. | Phase 2 |
| Active Not Recruiting | Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or NCT03065387 | M.D. Anderson Cancer Center | Phase 1 |
| Recruiting | APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid NCT03175224 | Apollomics Inc. | Phase 2 |
| Completed | Nimotuzumab and Nivolumab in Treating Patients With Advanced Non-small Cell Lung Cancer NCT02947386 | Roswell Park Cancer Institute | Phase 1 |
| Completed | Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475 NCT03049618 | University of Southern California | Phase 2 |
| Completed | Clinical Trial of YH25448 in Patients with EGFR Mutation Positive Advanced NSCLC NCT03046992 | Yuhan Corporation | Phase 1 / Phase 2 |
| Unknown | EGFR-TKI With/Without Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism NCT03002844 | Shanghai Pulmonary Hospital, Shanghai, China | Phase 2 |
| Terminated | Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR Mutations NCT02954523 | Chul Kim | Phase 1 / Phase 2 |
| Unknown | EGFR-TKIs Combine Chemotherapy as First-line Therapy for Patients With Advanced EGFR Mutation-positive NSCLC NCT02886195 | Fujian Cancer Hospital | Phase 3 |
| Completed | Afatinib in Lung Cancer With EGFR Mutation From Circulating Tumor DNA NCT02629523 | Chonnam National University Hospital | Phase 2 |
| Recruiting | Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy NCT03042221 | University of Colorado, Denver | — |
| Unknown | Metformin Plus TKI Use in Patients With Non-Small Cell Lung Carcinoma NCT03071705 | Instituto Nacional de Cancerologia de Mexico | N/A |
| Completed | The Molecular Epidemiology of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients With Advanced EGFR NCT04640870 | Hellenic Cooperative Oncology Group | — |
| Unknown | Comparator-Controlled Study for EGFR(+) Patients With Multiple BMs From NSCLC (BROKE) (EGFR-epidermal Growth F NCT02338011 | Shanghai Chest Hospital | Phase 2 / Phase 3 |
| Unknown | Erlotinib Combined With Chemotherapy in TKI Resistant Non-Small Cell Lung Cancers NCT02098954 | Hunan Province Tumor Hospital | Phase 2 |
| Completed | Frequency of EGFR and KRAS Mutations and Clinical-prognostic Correlation in Brazilian Lung Cancer Patients NCT03171636 | Hospital Erasto Gaertner | — |